353 related articles for article (PubMed ID: 12706354)
1. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.
Robertson JF; Blamey RW
Eur J Cancer; 2003 May; 39(7):861-9. PubMed ID: 12706354
[TBL] [Abstract][Full Text] [Related]
2. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
3. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
4. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
Jonat W
Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
[TBL] [Abstract][Full Text] [Related]
6. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
7. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
[TBL] [Abstract][Full Text] [Related]
8. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
9. Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women.
Jonat W
Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):1-5. PubMed ID: 11900209
[TBL] [Abstract][Full Text] [Related]
10. Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient.
Jonat W; Pritchard KI; Sainsbury R; Klijn JG
J Cancer Res Clin Oncol; 2006 May; 132(5):275-86. PubMed ID: 16435142
[TBL] [Abstract][Full Text] [Related]
11. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
; Cuzick J; Ambroisine L; Davidson N; Jakesz R; Kaufmann M; Regan M; Sainsbury R
Lancet; 2007 May; 369(9574):1711-23. PubMed ID: 17512856
[TBL] [Abstract][Full Text] [Related]
12. Overview of luteinizing hormone-releasing hormone agonists in early breast cancer-benefits of reversible ovarian ablation.
Jonat W
Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S23-6: discussion S33-5. PubMed ID: 12353820
[TBL] [Abstract][Full Text] [Related]
13. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
[TBL] [Abstract][Full Text] [Related]
14. Goserelin ('Zoladex')--offering patients more choice in early breast cancer.
Mitchell H
Eur J Oncol Nurs; 2004; 8 Suppl 2():S95-103. PubMed ID: 15590321
[TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer.
Hackshaw A; Baum M; Fornander T; Nordenskjold B; Nicolucci A; Monson K; Forsyth S; Reczko K; Johansson U; Fohlin H; Valentini M; Sainsbury R
J Natl Cancer Inst; 2009 Mar; 101(5):341-9. PubMed ID: 19244174
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
Boccardo F; Rubagotti A; Amoroso D; Mesiti M; Romeo D; Sismondi P; Giai M; Genta F; Pacini P; Distante V; Bolognesi A; Aldrighetti D; Farris A
J Clin Oncol; 2000 Jul; 18(14):2718-27. PubMed ID: 10894871
[TBL] [Abstract][Full Text] [Related]
17. Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.
Cheer SM; Plosker GL; Simpson D; Wagstaff AJ
Drugs; 2005; 65(18):2639-55. PubMed ID: 16392882
[TBL] [Abstract][Full Text] [Related]
18. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer.
Kaufmann M; Jonat W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; Schumacher M; Sauerbrei W;
Eur J Cancer; 2003 Aug; 39(12):1711-7. PubMed ID: 12888366
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
[TBL] [Abstract][Full Text] [Related]
20. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
Pritchard KI
Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]